Table 2.
Endocan levels in chronic HF patients in regard to patient's comorbidities.
| Comorbidity | N (%) | Endocan levels (median (IQR)) | p | |
|---|---|---|---|---|
| CAD | Yes | 57 (47) | 3.37 (2.39-4.76) | 0.976 |
| No | 63 (53) | 3.38 (2.48-4.85) | ||
| PAD | Yes | 22 (18) | 3.61 (2.32-4.97) | 0.218 |
| No | 98 (82) | 3.38 (2.48-4.85) | ||
| DM | Yes | 48 (40) | 3.51 (2.55-4.50) | 0.776 |
| No | 72 (60) | 3.25 (2.40-4.89) | ||
| AH | Yes | 84 (70) | 3.30 (2.34-4.75) | 0.292 |
| No | 36 (30) | 3.66 (2.82-5.01) | ||
| HLP | Yes | 70 (58) | 3.25 (2.28-4.28) | 0.401 |
| No | 50 (42) | 3.92 (2.58-5.31) | ||
| KI | Yes | 52 (43) | 3.55 (2.44-4.97) | 0.309 |
| No | 68 (57) | 3.26 (2.39-4.47) | ||
CAD: coronary artery disease; PAD: peripheral artery disease; DM: diabetes mellitus; AH: arterial hypertension; HLP: hyperlipidemia; KI: kidney insufficiency.